Attended 2025 BIOSeedin Conference (5/15-16/2025)
Attended 2025 ASCO Annual Conference
(5/30-6/3/2025)
NMPA approves L&L Bio's first Phase II/III clinical trial(8/06/2025)
Series B financing completed
(3/20/2023)
Participate in the finals of the China Innovation and Entrepreneurship Competition team category (7/31/2025)
Roadshow on Antibody China 2025
(2/27-28/2025)
LB1410 in combination with LB4330 Phase I/II NMPA approval
(3/11/2024)
Attended BIO US 2025 Conference
(6/16-19/2025)